Expression and clinical effect of the HBx protein mediated miR-143 in patients with hepatitis B hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-5820.2022.04.006

Abstract

Abstract:

Objective

To study the expression of HBx protein (Hepatitis B virus X antigen,HBx)and miR-143 in the serum of patients with hepatitis B related liver disease, and to explore the relationship between HBx protein and miR-143, and their roles in hepatitis B related liver cancer.

Methods

169 serum samples were collected from patients with HBV-related liver disease in the Laboratory Department of the Second Affiliated Hospital of Guangzhou Medical University. According to the course of hepatitis B disease, they were divided into chronic hepatitis B group (78 cases), HBV-related liver cirrhosis group (53 cases) and HBV-related liver cancer group (38 cases). Serum samples from 20 healthy people were selected as the control group. Serum HBx protein and hepatitis B were detected by ELISA; Serum miR-143 and HBV DNA were detected by Quantitative Real-time PCR(qPCR); AFP was detected by automatic chemiluminescence immunoassay (CLIA).

Results

The expression levels of miR-143 and AFP in HBx positive group were significantly higher than those in HBx negative group (P＜0.05); The positive rate of HBx and the expression of miR-143 in the high level group of hepatitis B virus replication were significantly higher than those in the other three groups (P＜0.05); The positive rate of HBx in liver cirrhosis group and liver cancer group was significantly higher than that in chronic hepatitis B group. The expression of serum miR-143 and AFP in liver cancer patients was significantly higher than that in the other three groups (P＜0.05); The relative expression of miR-143 in HBx positive group was significantly higher than that in HBx negative group (P＜0.05).

Conclusions

serum HBx is closely related to the expression of miR-143 in a dose-dependent manner. miR-143 may be involved in the progression of hepatitis B virus X protein mediated hepatitis B liver cancer. Both of them play an important role in the development of chronic hepatitis B into liver cancer, which provides a new direction for the diagnosis and treatment of hepatitis B liver cancer.

Key words: HBx protein, miR-143, Hepatitis B related liver cancer

Jinhong Zhu, Xueyan Li, Hong Wu, Zhen Lin, Qiang Zhou, Tianxing Ji. Expression and clinical effect of the HBx protein mediated miR-143 in patients with hepatitis B hepatocellular carcinoma[J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2022, 10(04): 222-226.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlcsysgldzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-5820.2022.04.006

https://zhlcsysgldzzz.cma-cmc.com.cn/EN/Y2022/V10/I04/222

Figures/Tables 4

References 26

1	Tarocchi M, Polvani S, Marroncini G, et al. Molecular mechanism of hepatitis B virus-inducedhepatocarcinogenesis[J]. World J Gastroenterol, 2014, 20(33): 11630-11640.
2	Pandyarajan V, Govalan R, Yang JD. Risk factors and biomarkers for chronic hepatitis B associated hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22(2): 479.
3	Sartorius K, Swadling L, An P, et al. The multiple roles of hepatitis B virus X protein(HBx) dysregulated microRNA in hepatitis B virus-associated hepatocellular carcinoma(HBV-HCC) and immune pathways[J]. Viruses, 2020, 12(7): 746.
4	Ali A, Abdel-Hafiz H, Suhail M, et al. Hepatitis B virus, HBx mutants and their roleinhepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(30): 10238-10248.
5	Xu J, An P, Winkler CA, et al. Dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma: potentialas biomarkers and therapeutic targets[J]. Front Oncol, 2020, 10: 1271.
6	郭苇, 谭为, 王昌俊. miRNA与肝癌的关系[J]. 广州中医药大学学报, 2015, 32(3): 569-572.
7	叶丽虹, 张伟英, 靳天志, 等. 乙肝病毒x蛋白结合蛋白在肿瘤发生发展中的作用[J]. 中国科学: 生命科学, 2019, 49(9): 1086-1099.
8	中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华传染病杂志, 2019, 37(12): 711-736.
9	朱锦宏, 王春苗, 吴红,等‍. 乙型肝炎病毒X基因siRNA对HeapG2.2.15细胞的影响[J]. 实用医学杂志, 2016, 32(13): 2120-2123.
10	Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29: 4781-4788.
11	Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma[J]. Hepatology, 2008, 47(3): 897-907.
12	Zhang XY, Liu SR, Hu TS, et al. Up-regulated microRNA-143 transcribed by nuclear factor kappa B enhances hepatocarcinoma metastasis by repressing fibronectin expression[J]. Hepatology, 2009, 50(2): 490-499.
13	敖家富, 冀文娟, 张静,等. HBV感染后慢性化进展过程中miRNA表达HBV基因型P基因点突变的研究[J]. 浙江临床医学, 2015, 17(2): 180-182.
14	Sagnelli E , Potenza N, Onorato L, et al. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma[J]. World J Hepatol, 2018, 10(9): 558-570.
15	Zhang ZQ, Meng H, Wang N, et al. Serum microRNA 143 and microRNA 215 as potential biomarkers for the diagnosis of chronic hepatitis and hepatocellular carcinoma[J]. Diagn Pathol, 2014, 9(1): 135.
16	Fiorino S, Bacchi-Reggiani ML, Visani M, et al. MicroRNAs as possible biomarkers for diagnosis and prognosis of hepatitis B- and C-related-hepatocellular-carcinoma[J]. World J Gastroenterol, 2016(15): 3907-3936.
17	Xu JH, An P, Winkler CA, et al. Dysregulated microRNAs in hepatitis B virus-related hepatocellular carcinoma: potential as biomarkers and therapeutic targets[J]. Front Oncol, 2020, 10: 1271.
18	Sagnelli E, Potenza N, Onorato L, et al. Micro-RNAs in hepatitis B virus-related chronic liver diseases and hepatocellular carcinoma[J]. World J Hepatol, 2018, 10(9): 558-570.
19	Sartorius K, Makarova J, Sartorius B, et al. The regulatory role of MicroRNA in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) pathogenesis[J]. Cells, 2019, 8(12): 1504.
20	袁俊建, 孔德帅, 陈雄飞, 等. miR-143, miR-145联合血清AFP检测对原发性肝癌的临床诊断价值[J]. 解放军医药杂志, 2019, 31(7): 29-32.
21	Zhao Q, Sun XF, Liu C, et al. Expression of the microRNA-143/145 cluster is decreased in hepatitis B virus-associated hepatocellular carcinoma and may serve as a biomarker for tumorigenesis in patients with chronic hepatitis B[J]. Oncology Lett, 2018, 15(5): 6115-6122.
22	Zhang JL, Huang J, Chen WD, et al. miR-143-3p targets lncRNA PSMG3-AS1 to inhibit the proliferation of hepatocellular carcinoma cells[J]. Cancer Manage Res, 2020, 12: 6303-6309.
23	谭式辉. 血清miR-143和miR-145水平诊断肝癌的临床价值研究[D]. 南宁: 广西医科大学, 2017.
24	Virzì A, Gonzalez-Motos V, Tripon S, et al. Profibrotic signaling and HCC risk during chronic viral hepatitis: biomarker development[J]. J Clin Med, 2021, 10(5): 977.
25	Nielsen KO, Jacobsen KS, Mirza AH, et al. Hepatitis B virus upregulates host microRNAs that target apoptosis-regulatory genes in an in vitro cell model[J]. Exp Cell Res, 2018, 371: 92-103.
26	Pan HY, Wu QQ, Yin QQ, et al. LC/MS-Based global metabolomic identification of serum biomarkers differentiating hepatocellular carcinoma from chronic hepatitis B and liver cirrhosis[J]. ACS Omega, 2021, 6(2): 1160-1170.

HBV DNA拷贝数（copies/ml）	例数	HBxAg		miR-143（2^–ΔΔCt值）
HBV DNA拷贝数（copies/ml）	例数	阳性［例（%）］	A_{450 mm}值中位数（min，max）	miR-143（2^–ΔΔCt值）
正常对照组	7	1（14.3）	0.34（0.017，0.80）	1.34±0.52
低水平组	66	14（21.2）	0.56（0.016，1.49）	2.23±0.78
中水平组	54	18（33.3）	0.96（0.031，2.02）	3.82±0.94
高水平组	42	22（52.4）^a	1.48（0.023，2.96）^a	4.64±0.87^a

HBV DNA拷贝数（copies/ml）	例数	HBxAg		miR-143（2^–ΔΔCt值）
HBV DNA拷贝数（copies/ml）	例数	阳性［例（%）］	A_{450 mm}值中位数（min，max）	miR-143（2^–ΔΔCt值）
正常对照组	7	1（14.3）	0.34（0.017，0.80）	1.34±0.52
低水平组	66	14（21.2）	0.56（0.016，1.49）	2.23±0.78
中水平组	54	18（33.3）	0.96（0.031，2.02）	3.82±0.94
高水平组	42	22（52.4）^a	1.48（0.023，2.96）^a	4.64±0.87^a

组别	例数	HBx蛋白［例（%）］	miR-143（2^–ΔΔCt值）	HBV DNA（lg）	AFP（lg ug/L）
慢性乙肝组	78	10（12.8）	1.21±0.58	4.78±1.25	1.09±0.25
肝硬化组	53	27（50.8）^a	2.37±0.97	4.55±0.77	2.44±0.38
肝癌组	38	18（47.4）^a	4.23±1.08^b	5.53±1.18^b	4.74±0.57^b
正常对照组	20	0（0.0）	1.53±0.36	0	1.03±0.33

组别	例数	HBx蛋白［例（%）］	miR-143（2^–ΔΔCt值）	HBV DNA（lg）	AFP（lg ug/L）
慢性乙肝组	78	10（12.8）	1.21±0.58	4.78±1.25	1.09±0.25
肝硬化组	53	27（50.8）^a	2.37±0.97	4.55±0.77	2.44±0.38
肝癌组	38	18（47.4）^a	4.23±1.08^b	5.53±1.18^b	4.74±0.57^b
正常对照组	20	0（0.0）	1.53±0.36	0	1.03±0.33

Please choose a citation manager

Content to export